Nature:ISIS滥用的精神药物芬乙茶碱,现可使用"疫苗解剖法"中和

2017-08-17 佚名 Nature自然科研

本周《自然》发表的一项小鼠研究Vaccine-driven pharmacodynamic dissection and mitigation of fenethylline psychoactivity显示,疫苗可以缓解人造精神兴奋剂芬乙茶碱的上瘾效果,并能鉴定其具有活性的化学成分。过去,人们就一直在努力鉴定导致芬乙茶碱快速展现其显着精神活性特征的具体成分,但是它独特的化学复杂性致使这些努力收效

本周《自然》发表的一项小鼠研究Vaccine-driven pharmacodynamic dissection and mitigation of fenethylline psychoactivity显示,疫苗可以缓解人造精神兴奋剂芬乙茶碱的上瘾效果,并能鉴定其具有活性的化学成分。过去,人们就一直在努力鉴定导致芬乙茶碱快速展现其显着精神活性特征的具体成分,但是它独特的化学复杂性致使这些努力收效甚微。

芬乙茶碱的商品名为芬乃他林,与中东地区的药物滥用和“药物恐怖主义”有关联。据估计,沙特阿拉伯40%的12-22岁的吸毒者对芬乙茶碱上瘾。

美国斯克里普斯研究所的Kim Janda及同事制定了一种名为“DISSECTIV”的“疫苗解剖”法,即通过对芬乙茶碱内的不同成分注射疫苗来确定那些对该药物中哪些成分产生了特定的行为效果。这种方法鉴定出了茶碱(常用于治疗呼吸道疾病的药物)和兴奋剂苯丙胺之间的功能性协同是芬乙茶碱之所以能产生其明显效果的来源。

使用该方法向小鼠增量注射针对芬乙茶碱成分的疫苗,在研究的第0、14、28天,发现芬乙茶碱的药效减弱了。作者的研究结果表明,对含有多成分混合物的单一化学物质逐渐增量注射疫苗,可用于发现药物作用于多种靶点或疾病通路的特性。他们认为DISSECTIV可用于发掘药物中未识别出的活性化学物质,并能揭示不同的复合药物如何相互发生作用。

注射FEN-KLH半抗原疫苗会产生针对芬乙茶碱及其活性代谢物的抗体。

Wenthur et al.
原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1812825, encodeId=04d01812825b7, content=<a href='/topic/show?id=ad4491016b7' target=_blank style='color:#2F92EE;'>#解剖法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91016, encryptionId=ad4491016b7, topicName=解剖法)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jan 26 20:55:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882376, encodeId=2a5918823e6d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Apr 16 09:55:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701549, encodeId=28771e01549dc, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Tue Jan 16 12:55:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402322, encodeId=6db11402322ba, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Aug 19 03:55:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586753, encodeId=80501586e5386, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Sat Aug 19 03:55:00 CST 2017, time=2017-08-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1812825, encodeId=04d01812825b7, content=<a href='/topic/show?id=ad4491016b7' target=_blank style='color:#2F92EE;'>#解剖法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91016, encryptionId=ad4491016b7, topicName=解剖法)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jan 26 20:55:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882376, encodeId=2a5918823e6d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Apr 16 09:55:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701549, encodeId=28771e01549dc, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Tue Jan 16 12:55:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402322, encodeId=6db11402322ba, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Aug 19 03:55:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586753, encodeId=80501586e5386, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Sat Aug 19 03:55:00 CST 2017, time=2017-08-19, status=1, ipAttribution=)]
    2018-04-16 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1812825, encodeId=04d01812825b7, content=<a href='/topic/show?id=ad4491016b7' target=_blank style='color:#2F92EE;'>#解剖法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91016, encryptionId=ad4491016b7, topicName=解剖法)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jan 26 20:55:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882376, encodeId=2a5918823e6d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Apr 16 09:55:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701549, encodeId=28771e01549dc, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Tue Jan 16 12:55:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402322, encodeId=6db11402322ba, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Aug 19 03:55:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586753, encodeId=80501586e5386, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Sat Aug 19 03:55:00 CST 2017, time=2017-08-19, status=1, ipAttribution=)]
    2018-01-16 zchen
  4. [GetPortalCommentsPageByObjectIdResponse(id=1812825, encodeId=04d01812825b7, content=<a href='/topic/show?id=ad4491016b7' target=_blank style='color:#2F92EE;'>#解剖法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91016, encryptionId=ad4491016b7, topicName=解剖法)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jan 26 20:55:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882376, encodeId=2a5918823e6d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Apr 16 09:55:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701549, encodeId=28771e01549dc, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Tue Jan 16 12:55:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402322, encodeId=6db11402322ba, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Aug 19 03:55:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586753, encodeId=80501586e5386, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Sat Aug 19 03:55:00 CST 2017, time=2017-08-19, status=1, ipAttribution=)]
    2017-08-19 hbwxf
  5. [GetPortalCommentsPageByObjectIdResponse(id=1812825, encodeId=04d01812825b7, content=<a href='/topic/show?id=ad4491016b7' target=_blank style='color:#2F92EE;'>#解剖法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91016, encryptionId=ad4491016b7, topicName=解剖法)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jan 26 20:55:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882376, encodeId=2a5918823e6d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Apr 16 09:55:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701549, encodeId=28771e01549dc, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Tue Jan 16 12:55:00 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402322, encodeId=6db11402322ba, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Aug 19 03:55:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586753, encodeId=80501586e5386, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Sat Aug 19 03:55:00 CST 2017, time=2017-08-19, status=1, ipAttribution=)]

相关资讯

BMJ:智障患者更易滥用精神药物

BMJ的一项新进研究表明,英国智障人士使用的精神药物远远超过治疗剂量。这表明,在某些情况下,智障人士存在精神药物滥用的情况,而不是用于治疗精神疾病。研究人员呼吁,有智力障碍的人应该合理精神药物剂量。研究人员发现,智障患者相比智力正常的民众而言,神经系统恶化的速度更快且患者更易出现暴力行为。精神药物滥用的情况已经存在多年,尤其是抗精神病药物(主要用于治疗精神分裂症和双相情感障碍)使用尤为广泛,但是患

Pediatrics:美国64%自闭儿童接受了精神药物治疗

根据《儿科学》(Pediatrics)10月21日在线发表的一篇报告,在一个包括33,000多例自闭症谱系障碍儿童患者的全美样本中,64%的儿童患者使用至少1种精神药物,35%使用多种精神药物。约15%接受多种精神药物治疗的儿童使用≥3类药物。多重用药的情况甚至在极年幼的儿童也较为常见,见于33%的2~10岁儿童和10%的≤1岁婴儿。研究者表示,上述结果令人担忧,因为目前缺乏证据证明儿童使用这些药